Leerink Partnrs Has Pessimistic View of ALNY Q2 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2025 earnings per share estimates for shares of Alnylam Pharmaceuticals in a report released on Tuesday, July 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the biopharmaceutical company will earn ($0.57) per share for the quarter, down from their previous estimate of ($0.42). The consensus estimate for Alnylam Pharmaceuticals' current full-year earnings is ($1.70) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals' Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($0.06) EPS and FY2027 earnings at $1.58 EPS.

Several other equities analysts also recently weighed in on ALNY. Bank of America lifted their target price on Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the company a "buy" rating in a research report on Friday, July 11th. JPMorgan Chase & Co. lifted their target price on Alnylam Pharmaceuticals from $338.00 to $348.00 and gave the company an "overweight" rating in a research report on Wednesday. Chardan Capital lifted their target price on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Finally, Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a "buy" rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $346.13.

Alnylam Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ ALNY traded down $4.16 during trading on Thursday, hitting $320.53. 581,322 shares of the company were exchanged, compared to its average volume of 852,491. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $333.70. The company has a debt-to-equity ratio of 8.88, a quick ratio of 2.98 and a current ratio of 3.04. The company has a fifty day moving average price of $306.46 and a 200-day moving average price of $271.53. The firm has a market capitalization of $41.79 billion, a PE ratio of -153.36 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative net margin of 11.49% and a negative return on equity of 510.31%. The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same period in the prior year, the company posted ($0.16) earnings per share. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Commonwealth Equity Services LLC increased its stake in Alnylam Pharmaceuticals by 23.3% during the fourth quarter. Commonwealth Equity Services LLC now owns 6,537 shares of the biopharmaceutical company's stock worth $1,538,000 after acquiring an additional 1,234 shares during the last quarter. Natixis Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 4.5% in the fourth quarter. Natixis Advisors LLC now owns 10,453 shares of the biopharmaceutical company's stock valued at $2,460,000 after buying an additional 451 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in shares of Alnylam Pharmaceuticals by 74.5% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,062 shares of the biopharmaceutical company's stock valued at $485,000 after buying an additional 880 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 6.0% in the fourth quarter. Intech Investment Management LLC now owns 7,573 shares of the biopharmaceutical company's stock valued at $1,782,000 after buying an additional 428 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.